In the world of high-stakes trials, Bart Williams is the relief pitcher to have in the bullpen. Williams, a partner at Proskauer Rose in Los Angeles, jumped into a $3.6 billion antitrust trial against the makers of two HIV drugs. After lead attorney Kirkland & Ellis partner James Hurst retired three months prior to trial, Williams joined the defense team for Gilead Sciences Inc., accused of conspiring with generic manufacturer Teva Pharmaceutical Industries Ltd. to delay the launch of two HIV medications.

On June 30, after more than five weeks of trial, a federal jury found that Gilead didn’t have market power—the first such antitrust verdict to side with the defense on that issue—and that no “pay for delay” deal existed between the two companies based on their 2014 patent settlement.